Literature DB >> 19707951

Cystoscopy and bladder biopsies in patients with bladder pain syndrome carried out following ESSIC guidelines.

Jean-Jacques Wyndaele1, Johan Van Dyck, Nele Toussaint.   

Abstract

OBJECTIVE: To evaluate the cystoscopy and histology of bladder biopsies conducted following the European Society for the Study of Interstitial Cystitis/Painful Bladder Syndrome (ESSIC) recommendations.
MATERIAL AND METHODS: This prospective study at a referral centre included 50 patients, with >12 on the O'Leary-Sant Interstitial Cystitis Symptom and Problem Indices and >7/10 on a visual analogue scale for average pelvic pain. Cystoscopic findings at hydrodistension and histological examination of biopsies were described as recommended by ESSIC and compared.
RESULTS: Performing the tests following ESSIC recommendations proved easy and offered information that permitted comparison between patients. Both cystoscopic and histological findings showed a large variation. There was no correlation between overall cystoscopic severity score and cystoscopic severity grade and the histological findings. There was a significant correlation between the cystoscopic aspect and inflammatory infiltration, mastocyte count in the detrusor muscle and stromal oedema. Maximal bladder capacity was negatively correlated with inflammation, mast cell count, haemorrhages and the overall cystoscopic aspect. In some patients cystoscopy and/or histology were normal. No information was available on patients with less severe symptoms.
CONCLUSIONS: Bladder pain syndrome (BPS) patients suffering from severe symptoms represent a group with various cystoscopic findings on hydrodistension and bladder histology carried out following ESSIC recommendations. Correlations between cystoscopic findings, maximal bladder capacity and bladder histology were found. For further typing of patients with BPS cystoscopy at hydrodistension and biopsies, may be considered to be mandatory. The use of the ESSIC methodology permits a standardized investigation with results that can be compared between patients.

Entities:  

Mesh:

Year:  2009        PMID: 19707951     DOI: 10.3109/00365590903199007

Source DB:  PubMed          Journal:  Scand J Urol Nephrol        ISSN: 0036-5599


  7 in total

1.  Commentary on "Cross-over data supporting long-term antibiotic treatment in patients with painful lower urinary tract symptoms, pyuria, and negative urinalysis".

Authors:  Sanjay Sinha
Journal:  Int Urogynecol J       Date:  2019-02-01       Impact factor: 2.894

Review 2.  Models of inflammation of the lower urinary tract.

Authors:  Dale E Bjorling; Zun-Yi Wang; Wade Bushman
Journal:  Neurourol Urodyn       Date:  2011-06       Impact factor: 2.696

3.  The Challenges of Interstitial Cystitis: Current Status and Future Prospects.

Authors:  Samuel Belknap; Eric Blalock; Deborah Erickson
Journal:  Drugs       Date:  2015-12       Impact factor: 9.546

Review 4.  Deciphering microRNA code in pain and inflammation: lessons from bladder pain syndrome.

Authors:  Ali Hashemi Gheinani; Fiona C Burkhard; Katia Monastyrskaya
Journal:  Cell Mol Life Sci       Date:  2013-03-05       Impact factor: 9.261

5.  Inhibition of nitric oxide synthase prevents muscarinic and purinergic functional changes and development of cyclophosphamide-induced cystitis in the rat.

Authors:  Patrik Aronsson; Renata Vesela; Martin Johnsson; Yasin Tayem; Vladimir Wsol; Michael Winder; Gunnar Tobin
Journal:  Biomed Res Int       Date:  2014-06-01       Impact factor: 3.411

6.  Cystoscopic findings in women with minimal and maximal lower urinary tract symptoms.

Authors:  Ioana Marcu; Jeffrey A Gavard; Golnar Vazirabadi; Joe Y Shi; Andrew C Steele; Fah Che Leong; Mary T McLennan; Jennifer A Bickhaus; Mary B Holloran-Schwartz; Patrick Yeung; Eugen C Campian
Journal:  Transl Androl Urol       Date:  2021-07

7.  Cystoscopic evaluation and clinical phenotyping in interstitial cystitis/bladder pain syndrome

Authors:  Ömer Acar; Tufan Tarcan
Journal:  J Turk Ger Gynecol Assoc       Date:  2018-11-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.